AML-432 Overall survival (OS) by IDH2 mutant allele (R140 or R172) in patients with late-stage, mutant-IDH2 relapsed/refractory acute myeloid leukemia (AML) treated with enasidenib or conventional care regimens (CCR) in the randomized, open-label, Phase 3 IDHENTIFY Trial
Κύριοι συγγραφείς: | , , , , , , , , , , , , , , , , |
---|---|
Μορφή: | Conference item |
Γλώσσα: | English |
Έκδοση: |
Elsevier
2022
|